title: Tumor hypoxia is a therapeutic target in soft-tissue sarcoma.
abstract: TH-302 shows antitumor activity in combination with doxorubicin in advanced soft-tissue sarcoma.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015687:Cell Hypoxia; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000009:adverse effects; D010752:Phosphoramide Mustards / Q000008:administration & dosage / Q000009:adverse effects; D012509:Sarcoma / Q000188:drug therapy*; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D009593:Nitroimidazoles; D010752:Phosphoramide Mustards; C552526:TH 302; D004317:Doxorubicin